Efficacy and safety of paclitaxel liposome combined with cisplatin in the treatment of advanced non-small cell lung cancer
10.3969/j.issn.1671-8348.2013.33.020
- VernacularTitle:紫杉醇脂质体联合顺铂治疗晚期非小细胞肺癌的疗效及安全性分析
- Author:
Lijuan WAN
- Publication Type:Journal Article
- Keywords:
carcinoma,non-small cell lung;
cisplatin;
advanced;
paclitaxel
- From:
Chongqing Medicine
2013;(33):4028-4029
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effects and toxicity of paclitaxel liposome combined with cisplatin in the treatment of ad-vanced non-small cell lung cancer .Methods 80 cases of patients of advanced non-small cell lung cancer were randomly divided into study group and control group ,40 cases in each group .Study group was treated with paclitaxel liposome (135 mg/m2 ,IV drip 3 h , first days) ,control group received paclitaxel(135 mg/m2 ,IV drip 3 h ,first days) ,the two groups combined with cisplatin 75 mg/m2 ,IV drip ,for 3 days ,take 21 days as one cycle .Results The study group CR 0 .0% (0/40) ,PR 27 .5% (11/40) ,RR 27 .5% (11/40);control group CR 0 .0% (0/40) ,PR 25 .0% (10/40) ,PR 25 .0% (10/40) ,(P>0 .05) .The research group of rash ,muscle and joint pain ,peripheral neuropathy was significantly lower than that of the control group (P<0 .05) .The research group of progres-sion-free survival was 5 .3 months(95% CI 3 .713 -6 .408) ,the median survival period was 9 .3 months(95% CI 8 .337 -9 .907);control group of progression-free survival was 4 .6 months(95% CI 3 .187 -5 .547) ,the median survival period was 9 .4 months (95% CI 7 .787-11 .602) ,the two groups had no statistical significance (P>0 .05) .Conclusion Paclitaxel liposome combined with cisplatin in treatment of advanced non-small cell lung cancer clinical efficacy and long-term efficacy of taxol and quite ,but with less allergic reaction .
